NCT07651124 To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
| NCT ID | NCT07651124 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yong Wha Moon |
| Condition | Recurrent Ovarian Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6 participants in total. It began in 2025-04-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.
Eligibility Criteria
Inclusion Criteria: * Recurrent ovarian cancer * There is a cancerous lesion that can be removed by biopsy or surgery. Exclusion Criteria: * Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy * Patient deemed unsuitable by the principal investigator
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07651124 clinical trial?
This trial is open to female participants only, aged 20 Years or older, studying Recurrent Ovarian Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07651124 currently recruiting?
Yes, NCT07651124 is actively recruiting participants. Contact the research team at ymoon@cha.ac.kr for enrollment information.
Where is the NCT07651124 trial being conducted?
This trial is being conducted at Gyeonggi-do, South Korea.
Who is sponsoring the NCT07651124 clinical trial?
NCT07651124 is sponsored by Yong Wha Moon. The trial plans to enroll 6 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.